
News|Articles|October 1, 2003
Wyeth reports off-label use of venlafaxine associated with pediatric risks
A recent "Dear Healthcare Professional" letter issued by Wyeth outlines the potential risks associated with the company's antidepressant venlafaxine (Effexor and Effexor XR) when the drug is administered in the pediatric population. The letter, dated August 22, 2003, cites data from clinical studies in pediatric patients (aged 617 y) and details changes that have been made to the labeling for venlafaxine. Venlafaxine has been prescribed off-label in the pediatric population despite never being approved by FDA for use in children or adolescents.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
2
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
3
A conversation with Dolores Malaspina, M.D., about the generational impact of Holocaust trauma on schizophrenia risk
4
Intervention boosts connected insulin pen adoption among minorities with Type 1 diabetes
5


























